NARCAN injection (naloxone hydrochloride) has become listed on the Pharmaceutical Benefits Scheme effective from today, with the move welcomed by the product's sponsor, Australian specialty pharmaceutical manufacturer Phebra.
Narcan is a medicine used to reverse the effects of overdoses of opioid drugs and for the diagnosis of suspected acute opioid overdoses, with Phebra ceo Mal Eutick saying it has been successfully used across Australia by frontline paramedics to save the lives of people suffering overdoses.
Narcan injection is now available for reimbursement on the PBS for Prescriber Bag Supply Only.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Feb 18
